STUDI KARAKTERISTIK DAN PENGGUNAAN OBAT PADA PENDERITA HEPATITIS B DI RUMAH SAKIT PEMERINTAH KOTA MANADO PERIODE JANUARI 2011 – DESEMBER 2012

Lady zha-zha Luntungan, Fatimawali Fatimawali, Widdhi Bodhi

Abstract


ABSTRACT
Hepatitis B is a disease caused by the virus called hepatitis B wich characterized by an
inflammation that occurs in organs such as the liver. The transmission of Hepatitis B is higher
than the transmission of the HIV virus. This study aimed to investigate the characteristics and
use of the drug in hepatitis B patients in the Government Hospital in Manado. This research
is a descriptive study based on retrospective data collection for 2 years survey from January
2011 to December 2012. The respondent of this research involve of 70 patients with Hepatitis
B medical record. The results showed that based on group age, responden with age group 46-
65 has the highest percentage by 31 patients (44.3%), based on gender, males have the
highest percentage of total of 47 patients (67.1%), based on the duration of treatment, the
highest percentage is shown by the patient with 1 day threatment as 21 patients (30%). Based
on therapeutic treatment this research divided it into 2 kind of threatment. The first us single
agent therapy Hepamax consist of 27 patients (38.6%) The second therapy is combination
between Hepamax and Curcuma wich consist of 9 patients (12.9%). This research conducted
based on 100% oral route of medicine threatment.
Keywords: Hepatitis B, Hepatitis B medicine, Singel Therapy, Combination Therapy

Full Text:

PDF


DOI: https://doi.org/10.35799/pha.2.2013.2381

Refbacks

  • There are currently no refbacks.


Copyright (c)



 

 

Publisher :
Pharmacy Study Program,
Faculty of Mathematic and Science
Sam Ratulangi University
Manado, North Sulawesi, Indonesia, 95115

     

Cooperation With :
Persatuan Ahli Farmasi Indonesia (PAFI)
Sulawesi Utara
Manado, North Sulawesi, Indonesia, 95112

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.